Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease

2003 ◽  
Vol 111 (1) ◽  
pp. 180-186 ◽  
Author(s):  
M.Pilar Berges-Gimeno ◽  
Ronald A. Simon ◽  
Donald D. Stevenson
Keyword(s):  
Respiratory Disease ◽  
Term Treatment ◽  
Aspirin Desensitization ◽  
Asthmatic Patients ◽  
Aspirin Exacerbated Respiratory Disease ◽  
Long Term Treatment

Long-term Sinonasal Outcomes of Aspirin Desensitization in Aspirin Exacerbated Respiratory Disease

2014 ◽  
Vol 151 (4) ◽  
pp. 575-581 ◽  
Author(s):  
Kyu-Sup Cho ◽  
Ethan Soudry ◽  
Alkis J. Psaltis ◽  
Kari C. Nadeau ◽  
Sean A. McGhee ◽  
...  
Keyword(s):  
Respiratory Disease ◽  
Aspirin Desensitization ◽  
Aspirin Exacerbated Respiratory Disease

scholarly journals Severe Allergic Bronchopulmonary Mycosis and Long-Term Follow-Up

2018 ◽  
Vol 2018 ◽  
pp. 1-5
Author(s):  
Hossein Esmaeilzadeh ◽  
Sara Kashef ◽  
Hamid Reza Hatami ◽  
Soheila Alyasin ◽  
Hesamodin Nabavizadeh ◽  
...  
Keyword(s):  
Immunoglobulin E ◽  
Allergic Bronchopulmonary Aspergillosis ◽  
Fungal Species ◽  
Term Treatment ◽  
High Resolution Computed Tomography ◽  
Asthmatic Patients ◽  
Long Term Treatment ◽  
Allergic Bronchopulmonary Mycosis ◽  
Fungal Allergen

Allergic bronchopulmonary aspergillosis (ABPA) is the most common immunologic reaction following fungal allergen exposure in asthmatic patients. A less frequent syndrome in response to other fungal species like candida is allergic bronchopulmonary mycosis (ABPM). This reaction is mostly associated with asthma exacerbation, changes in Immunoglobulin E levels, and nonspecific findings in high resolution computed tomography (HRCT). This study presents a 9-year-old girl, a known case of childhood asthma, resolved 4 years ago as a novel case of ABPM due to Candida albicans manifested by severe emphysema, bronchiectasis, and pneumothorax which consequently required long-term treatment to get relieved.

Nocturia in Patients on Long-Term Steroid Therapy

1970 ◽  
Vol 38 (4) ◽  
pp. 415-425 ◽  
Author(s):  
J. P. Thomas ◽  
G. A. Coles ◽  
A. H. El-Shaboury
Keyword(s):  
Circadian Rhythm ◽  
Term Treatment ◽  
Tubular Reabsorption ◽  
Electrolyte Excretion ◽  
Asthmatic Patients ◽  
Long Term Treatment ◽  
Proximal Tubular ◽  
Stopping Treatment ◽  
Proximal Tubular Reabsorption

1. About half of our asthmatic patients on long-term treatment with prednisone developed nocturia. 2. This is due to reversal of the normal circadian rhythm of water and electrolyte excretion and is partially corrected within 48 hr of stopping treatment. 3. The disturbance in water and electrolyte excretion appeared to be due to a decrease in proximal tubular reabsorption of sodium at night. This was not directly related to a change in the secretion of Cortisol, aldosterone or antidiuretic hormone.

Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily

Allergy ◽  
2008 ◽  
Vol 63 (9) ◽  
pp. 1228-1234 ◽  
Author(s):  
A. Rozsasi ◽  
D. Polzehl ◽  
T. Deutschle ◽  
E. Smith ◽  
K. Wiesmiller ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Term Treatment ◽  
Prospective Clinical Trial ◽  
Aspirin Desensitization ◽  
Long Term Treatment

Long-term Clinical Outcomes of Aspirin Desensitization With Continuous Daily Aspirin Therapy in Aspirin-exacerbated Respiratory Disease

2018 ◽  
Vol 32 (4) ◽  
pp. 280-286 ◽  
Author(s):  
Kristen M. Walters ◽  
Jeremy D. Waldram ◽  
Katharine M. Woessner ◽  
Andrew A. White
Keyword(s):  
Respiratory Disease ◽  
Average Length ◽  
Airway Disease ◽  
Sinus Surgery ◽  
Response To Treatment ◽  
Aspirin Desensitization ◽  
Aspirin Exacerbated Respiratory Disease ◽  
Systemic Corticosteroids ◽  
Samter’S Triad

Background Aspirin-exacerbated respiratory disease (AERD), also known as Samter’s triad or aspirin (ASA)-intolerant asthma, affects 7% of asthmatics and has a higher prevalence in those with chronic rhinosinusitis and concomitant nasal polyposis. ASA desensitization with daily ASA therapy is a uniquely beneficial treatment for this disease entity and has been shown to have a significant impact on symptom scores, polyp disease, and need for systemic corticosteroids. However, no long-term studies have demonstrated whether or not ASA therapy remains safe and beneficial for these patients beyond 5–10 years. Objective This study was designed to determine the clinical course of AERD patients desensitized between 1995 and 2010. Methods A 20-question survey was distributed to patients who successfully completed ASA desensitization between January 1995 and April 2010. The questions were designed to assess ASA safety and longitudinal effects of ASA therapy in AERD. Results Of the 285 patients contacted, 92 (32%) completed the questionnaire. Average length of follow-up was 15 years. Of survey responders, 35 patients had discontinued ASA therapy. Although adverse reactions occurred, many also discontinued due to lack of efficacy or need for surgery. For those remaining on ASA (62%), significant improvement in sense of smell, asthma, sinus, and allergic rhinitis scores were noted ( P ≤ .001). The majority of ASA patients (68%) had a positive response to treatment and did not require further sinus surgery. However, ASA therapy did not delay the time to next sinus/polyp surgery ( P = .27) or reduce total number of sinus surgeries ( P = .56) compared to those who stopped treatment. Nearly 85% of AERD patients on ASA therapy found it to be helpful in improving airway disease and quality of life. Conclusion Aspirin desensitization followed by daily maintenance ASA therapy appears to be safe and effective even after 10+ years of continuous use.

Sign in / Sign up

Export Citation Format

Share Document